Savara (SVRA) Deferred Taxes (2018)
Savara (SVRA) reported Deferred Taxes of -$2.5 million for Q4 2018, up 45.07% quarter-over-quarter from -$4.6 million in Q1 2018.
Savara (SVRA) Deferred Taxes (2018) Analysis & Trends
Savara (SVRA) has 1 years of Deferred Taxes data on file, last reported at -$2.5 million in Q4 2018.
- Deferred Taxes for Q4 2018 came in at -$2.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was -$7.1 million (changed N/A YoY), and the FY2018 annual result was -$7.1 million, down 150.25% from the prior year.
- Deferred Taxes advanced to -$2.5 million in Q4 2018 per SVRA's latest filing, from -$4.6 million in the prior quarter.
- Over five years, Deferred Taxes peaked at -$2.5 million in Q4 2018 and troughed at -$4.6 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -859,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -65.30 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -2.50 Mn |
| Mar 31, 2018 | -4.56 Mn |